Biontech Se
No standout activity across the feeds we track.
What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2025-08-07 | Val T. Hoyle · D-OR | House | Sold | $1,001 - $15,000 |
| 2024-09-03 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2024-08-30 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2024-04-15 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2024-03-14 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2023-12-07 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2023-12-06 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2023-12-05 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.